Advances in Neurofibromatosis
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 5 July 2025 | Viewed by 25
Special Issue Editors
Interests: neurofibromatosis; schwannomatosis; rare genetic disorders; clinical molecular genetics and cytogenetics; bioinformatics
Special Issue Information
Dear Colleagues,
Neurofibromatosis (NF) is a group of genetic disorders characterized by neurological and cutaneous manifestations. It includes neurofibromatosis type 1 (NF1), NF2-related schwannomatosis (previously known as neurofibromatosis type 2 or NF2), SMARCB1- and LZTR1-related schwannomatosis, and schwannomatosis without NF2, SMARCB1, and LZTR1 pathogenic variants in the blood. Recent advancements in NF research have brought new hope and improved outcomes for individuals affected by these complex genetic disorders.
This Special Issue aims to showcase the latest research on NF. We invite you to share your research and insights through original research articles and reviews.
Potential research areas for this Special Issue include, but are not limited to, the following:
- Molecular and genetic mechanisms underlying NF;
- Novel phenotype-genotype correlations in NF;
- Novel methods and recommendations for variant classification in genes associated with NF;
- Innovative diagnostic techniques in NF;
- Novel therapeutic targets in NF;
- Novel biomarkers for NF;
- Clinical trials exploring innovative therapeutic approaches for NF patients;
- Guidelines for the diagnosis and management of NF.
If you have any questions or require further information or assistance, please do not hesitate to reach out to us. We are here to support and facilitate your participation in this Special Issue. We look forward to receiving your submissions.
Dr. Yunjia Chen
Dr. Yulong Fu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurofibromatosis
- schwannomatosis
- NF1
- NF2
- SMARCB1
- LZTR1
